Bulletin of Experimental Biology and Medicine

, Volume 124, Issue 4, pp 1008–1010 | Cite as

Androstenedione conversion in lymphocytes infiltrating breast tumor tissue

  • L. M. Bershtein
  • T. E. Poroshina
  • T. S. Zimarina
  • A. A. Larionov
  • A. V. Uporov
Oncology
  • 27 Downloads

Abstract

Lymphocytes infiltrating tumor tissue are capable of androstenedione conversion, which was assessed from3H2O release from tritium-labeled androgen precursor of estrogens 1β-androstenedione. This capacity is higher in menopausal patients than in patients of reproductive age. A tendency to a positive correlation between the intensity of androstenedione conversion in lymphocytes and aromatase activity in tumor tissue is revealed. No relationship between androstenedione conversion in lymphocytes and contamination of the isolated cell suspension with tumor cells is detected.

Key Words

lymphocytes lymphocytic infiltration breast cancer estrogens 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    L. M. Bershtein, A. A. Larionov, and O. G. Kryukova,Byull. Eksp. Biol. Med.,117, No. 5, 517–519 (1994).CrossRefGoogle Scholar
  2. 2.
    L. M. Bershtein, A. A. Larionov, A. Sh. Kyshtoobaeva,et al., ——Ibid.,,120, No. 10, 410–413 (1995).Google Scholar
  3. 3.
    L. M. Bershtein, T. E. Poroshina, E. V. Tsyrlina,et al., Vopr. Onkol., No. 5, 36–39 (1996).Google Scholar
  4. 4.
    S. Aaltomaa, P. Lipponen, M. Eskelinen,et al., Eur. J. Cancer Clin. Oncol.,28A, 859–864 (1992).Google Scholar
  5. 5.
    A. Belldegrun, A. Kasid, M. Uppenkamp,et al., J. Immunol.,142, 4520–4526 (1989).PubMedGoogle Scholar
  6. 6.
    L. M. Berstein, A. A. Larionov, A. Sh. Kyshtoobaeva,et al., J. Cancer Res. Clin. Oncol.,122, 495–498 (1996).PubMedCrossRefGoogle Scholar
  7. 7.
    L. M. Berstein, R. J. Santen, and S. J. Santner,Med. Hypotheses,45, 588–590 (1995).PubMedCrossRefGoogle Scholar
  8. 8.
    L. M. Berstein, S. J. Santner, A. M. Brodie,et al., J. Steroid Biochem. Mol. Biol.,44, 647–649 (1993).PubMedCrossRefGoogle Scholar
  9. 9.
    H. O. Besedowsky and A. DelRey,Endocr. Rev.,17, 64–102 (1996).CrossRefGoogle Scholar
  10. 10.
    H. S. Feigelson and B. Henderson,Carcinogenesis,17, 2279–2284 (1996).PubMedGoogle Scholar
  11. 11.
    M. J. Reed, A. Purohit, L. J. Duncanet al., J. Steroid Biochem. Mol. Biol.,53, 413–420 (1995).PubMedCrossRefGoogle Scholar
  12. 12.
    R. J. Santen, J. Martel, M. Hoagland,et al., J. Clin. Endocrinol. Metab.,79, 627–632 (1994).PubMedCrossRefGoogle Scholar
  13. 13.
    E. R. Simpson, M. S. Mahendroo, G. D. Means,et al., Endocr. Rev.,15, 342–355 (1994).PubMedCrossRefGoogle Scholar
  14. 14.
    R. P. Tang, B. Kacinski, P. Validire,et al., J. Cell. Biochem.,44, 189–198 (1990).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1998

Authors and Affiliations

  • L. M. Bershtein
    • 1
  • T. E. Poroshina
    • 1
  • T. S. Zimarina
    • 1
  • A. A. Larionov
    • 1
  • A. V. Uporov
    • 1
  1. 1.N. N. Petrov Institute of OncologySt. Petersburg

Personalised recommendations